IO Biotech

IO Biotech R&D per Employee

Delisted·Sep 22, 2026

The R&D Spending per Employee of IO Biotech (IOBT) as of Nov 20, 2026 is 1.25 M USD. In the previous year, R&D Spending per Employee was 1.19 M USD — a change of 5.39% (higher).

R&D per Employee

1.25 MUSD

YoY

5.39%

Last updated:

R&D Spending per Employee of IO Biotech is 2024 1.25 M USD. R&D Spending per Employee of IO Biotech was 2023 1.19 M USD. It decreases by 5.39% higher compared to the previous year.

The IO Biotech R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
139,245.61 USD
Jan 1, 2020
148,491.23 USD
Jan 1, 2021
528,982.46 USD
Jan 1, 2022
824,315.79 USD
Jan 1, 2023
1.19 M USD
Jan 1, 2024
1.25 M USD
The IO Biotech R&D per Employee history
YEARR&D per EmployeeYoY
1.25 MUSD+5.39%
1.19 MUSD+44.36%
824,315.79USD+55.83%
528,982.46USD+256.24%
148,491.23USD+6.64%
139,245.61USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech, Inc. develops immune modulating cancer therapies using its T-win technology platform. The Company focuses on product candidates that target immunosuppressive proteins like IDO and PD-L1, aiming to disrupt tumor-induced immunosuppression. Its lead candidate, IO102-IO103, is designed to address multiple pathways regulated by these proteins. The firm's pipeline includes therapies leveraging T-win to target the tumor microenvironment (TME). IO Biotech's revenue model is based on the development and potential commercialization of its product candidates. The company generates income through partnerships with pharmaceutical firms for the development and licensing of its therapies. These partnerships are formed with entities interested in advancing immune modulating cancer treatments. The target market includes pharmaceutical companies seeking innovative cancer therapy solutions. The firm's technology platform, T-win, is central to its business strategy. By targeting key immunosuppressive proteins such as IDO and PD-L1, IO Biotech addresses a critical need in cancer treatment. Its lead product candidate, IO102-IO103, is positioned to disrupt multiple immunosuppressive pathways, offering a novel approach to cancer therapy. IO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IO Biotech stock

R&D Spending per Employee of IO Biotech is 1.25 M USD in 2024.

R&D Spending per Employee of IO Biotech changed from 1.19 M USD to 1.25 M USD, representing a 5.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee IO Biotech since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's IO Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — IO Biotech

All Key Metrics — IO Biotech